Nobmetapharma Secures New Pipeline

ResearchAlum Report

[Asia Economy Reporter Hyungsoo Park] Research Alom analyzed that Nobmeta Pharma, a KONEX market-listed company, has a high possibility of transferring to KOSDAQ through the adoption of the technology special listing system.

Lee Donghyun, Senior Researcher at Research Alom, explained, "Since they have not yet licensed out or commercialized new drug development, no sales occur other than health functional food sales," adding, "they have appointed a new designated advisor and are accelerating their initial public offering (IPO)."

He continued, "It is expected that they will choose the technology special listing system instead of the fast track in the IPO process," and added, "Since they have already passed the technology evaluation twice in 2018 and 2019, there is great expectation for completion."

Furthermore, he analyzed, "One of the considerations when investing in bio companies is the potential for pipeline expansion," and "They are developing treatments for metabolic diseases, which form a global market worth 70 trillion KRW."

The researcher advised, "Recently, by merging with their subsidiary Nobmeta Health, they are expected to add pipelines for pancreatitis, liver cancer, and others," emphasizing, "The core consideration before investing in bio companies is the pipeline."

He emphasized, "By expanding the indications of the pipeline, a broad patient group across various diseases can be secured," and "Nobmeta Pharma is expanding new pipelines for various diseases such as pulmonary fibrosis, peritoneal fibrosis, and inflammatory bowel disease, centered on core pipelines close to commercialization like obesity and diabetes."

Nobmeta Pharma is developing treatments for metabolic diseases. In November last year, they applied for Phase 2 clinical trials with the U.S. FDA for four major pipelines: non-alcoholic steatohepatitis, diabetic kidney disease, chronic kidney disease, and idiopathic pulmonary fibrosis.

This content was produced with the assistance of AI translation services.